Metabolic Syndrome Strikes Nearly Half of Women With PCOS in Hospital Study

Polycystic ovary syndrome has long been framed as a reproductive disorder, a condition that sends women to fertility clinics seeking answers about irregular cycles and difficulty conceiving. A new hospital-based study from Pune, India, adds weight to a very different and increasingly urgent framing: PCOS is, for many women, a metabolic disease in waiting. In a cross-sectional analysis of 480 women diagnosed with PCOS at a tertiary care hospital, researchers found that 43.8 percent met the criteria for metabolic syndrome, a cluster of abnormalities that dramatically raises the risk of type 2 diabetes and cardiovascular disease. The finding, published in Discover Social Science and Health, underscores how frequently the reproductive and metabolic dimensions of PCOS travel together, and how often the metabolic half of the equation goes unexamined.

The study team, led by Riti Chakraborty of Dr D Y Patil Medical College in Pune, recruited women aged 15 to 40 years from the gynecology outpatient department using convenience sampling during the study period. Every participant met the Rotterdam criteria, the internationally accepted diagnostic standard for PCOS, which requires two of three features: irregular or absent ovulation, clinical or laboratory evidence of elevated androgens, and the characteristic polycystic ovarian morphology on ultrasound. Once enrolled, the women underwent a standardized clinical and biochemical workup. Anthropometric measurements captured height, weight, body mass index, and waist circumference; blood pressure was recorded; and fasting blood samples were analyzed for glucose, triglycerides, and high-density lipoprotein cholesterol, the so-called good cholesterol that helps clear fat from the bloodstream.

Defining metabolic syndrome required a deliberate methodological choice. The researchers applied the modified National Cholesterol Education Program Adult Treatment Panel III criteria, a widely used framework under which a patient is classified as having metabolic syndrome when three or more of five abnormalities are present: elevated waist circumference, elevated triglycerides, low HDL cholesterol, elevated fasting glucose, and elevated blood pressure. Critically, the team incorporated the South Asian-specific waist circumference threshold of 80 centimeters or more, a lower cutoff than the one used for European populations. That adjustment matters. South Asian women accumulate visceral, metabolically active fat at lower body weights and smaller waist sizes than many other populations, and using a generic threshold would have systematically underestimated central obesity in this cohort.

The headline number, 43.8 percent, carries a 95 percent confidence interval of 39.4 to 48.3 percent, meaning the true prevalence in the underlying population plausibly falls between roughly four in ten and nearly one in two women with PCOS attending this hospital. Behind that aggregate figure sits a detailed portrait of which metabolic abnormalities dominate. Low HDL cholesterol was by far the most common derangement, present in 81.3 percent of the women. Central obesity, the accumulation of fat around the abdomen measured by the waist threshold, affected 58.3 percent. Hypertriglyceridemia, elevated levels of circulating blood fats, was found in 41.7 percent. This pattern, in which atherogenic dyslipidemia and abdominal adiposity dominate the metabolic picture, is characteristic of insulin resistance, the physiological thread that connects PCOS to cardiovascular risk.

The mechanism most often invoked to explain this clustering is insulin resistance with compensatory hyperinsulinemia. When tissues respond poorly to insulin, the pancreas secretes more of the hormone to maintain normal blood sugar, and those chronically elevated insulin levels act on the ovary to increase androgen production while simultaneously promoting central fat deposition and altering hepatic lipid metabolism in ways that lower HDL and raise triglycerides. The study’s biochemical comparisons give this picture quantitative texture. Women with metabolic syndrome had significantly higher mean body mass index, waist circumference, fasting blood glucose, triglyceride levels, and blood pressure, and significantly lower HDL cholesterol, than women without the syndrome, with every one of those differences reaching the stringent threshold of p less than 0.001.

Two demographic gradients stood out with particular clarity. Prevalence of metabolic syndrome rose steeply across age groups, a relationship that was statistically robust at p less than 0.001, and it peaked at 58.8 percent among women aged 30 to 34 years. It also climbed across body mass index categories, again at p less than 0.001, reaching a striking 84.6 percent among women with obesity. In other words, in this cohort, obesity and metabolic syndrome were nearly synonymous: fewer than one in six women with PCOS and obesity escaped the syndrome’s diagnostic cluster. The authors are careful to frame these as associations rather than proof that age or body mass index independently cause metabolic syndrome, a caution rooted in the study’s design.

That design deserves scrutiny, because it shapes what the numbers can and cannot tell us. As a descriptive cross-sectional study conducted at a single tertiary care center with convenience sampling, it captures a snapshot of women who presented to a hospital gynecology clinic, a group that is likely to be more symptomatic, more health-conscious, or more medically complex than women with PCOS in the general community. Prevalence estimates drawn from tertiary care populations typically run higher than community-based figures, and the authors explicitly state that their findings may not be directly generalizable to women with PCOS in community or other healthcare settings. Convenience sampling, in which participants are enrolled as they become available rather than through a randomized frame, further limits the strength of population-level inference.

The temporal limitation is equally important. Cross-sectional data measure exposure and outcome at the same moment, so they cannot establish whether higher body mass index precedes metabolic syndrome, whether insulin resistance drives weight gain, or whether both emerge from shared upstream causes. The authors state plainly that the observed associations should be interpreted as associations rather than evidence of independent predictors or causal relationships, and they call for prospective multicenter studies to identify the independent determinants of metabolic syndrome in PCOS and to establish the temporal sequence of events. Such studies, following women over years rather than photographing them once, would also clarify whether early intervention can bend the risk curve.

Even with those caveats, the clinical message is difficult to ignore. Metabolic syndrome at nearly 44 percent prevalence among reproductive-aged women represents a substantial reservoir of future diabetes and cardiovascular disease, and the dominant abnormalities identified here, low HDL cholesterol, central obesity, and hypertriglyceridemia, are precisely the abnormalities most responsive to early lifestyle intervention. Weight reduction, dietary modification, and physical activity have well-documented effects on each of these parameters, and the authors argue that their findings support routine metabolic screening and early lifestyle-based interventions for women with PCOS. The practical implication is that a diagnosis of PCOS should trigger more than a reproductive workup; it should prompt measurement of waist circumference, fasting glucose, and a lipid panel, ideally at diagnosis and periodically thereafter, particularly as women age or gain weight.

The study also carries a broader significance for how medicine partitions disease. PCOS affects an estimated one in ten women of reproductive age worldwide, and if metabolic syndrome is present in a comparable or substantial fraction of them, the condition belongs as much in the cardiometabolic clinic as in the fertility clinic. The Pune data, gathered under the Declaration of Helsinki with ethics approval from Dr. D. Y. Patil University and written informed consent from all participants, including parental consent and age-appropriate assent for those younger than 16, offer a detailed, methodologically transparent snapshot of that reality in a South Asian population. They confirm that the lower, population-specific waist threshold changes who gets counted, that the metabolic burden of PCOS concentrates among older and heavier patients, and that the window for prevention may open years before diabetes or heart disease announces itself. What remains to be established, through the longitudinal and multicenter work the authors call for, is whether that window can be closed in time.

Subject of Research: Prevalence and metabolic risk profile of metabolic syndrome among women with polycystic ovary syndrome

Article Title: Metabolic syndrome prevalence clinical profile and associated metabolic risk factors among women with polycystic ovary syndrome in a tertiary care setting

Article References: Chakraborty, R., Kulkarni, J., Jagdale, S., Sunil, L., Sudev, K. R., Garg, P., & Mandal, B. (2026). Metabolic syndrome prevalence clinical profile and associated metabolic risk factors among women with polycystic ovary syndrome in a tertiary care setting. Discover Social Science and Health. https://doi.org/10.1007/s44155-026-00496-2

Image Credits: AI Generated

DOI: 10.1007/s44155-026-00496-2

Keywords: polycystic ovary syndrome, metabolic syndrome, insulin resistance, dyslipidemia, central obesity, HDL cholesterol, triglycerides, body mass index, cardiometabolic risk, cross-sectional study, South Asian women, tertiary care